mitogen-activated protein kinase kinase 5

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help


Alternate Names:  PRKMK5
Alternate Symbols:  HsT17454; MAPKK5; MEK5
PharmGKB Accession Id: PA30590


Cytogenetic Location: chr15 : q23 - q23
GP mRNA Boundary: chr15 : 67835021 - 68099455
GP Gene Boundary: chr15 : 67825021 - 68102455
Strand: plus


UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

External Pathways

Links to non-PharmGKB pathways.

  1. mapkinase signaling pathway - (BioCarta via Pathway Interaction Database)
  2. role of erk5 in neuronal survival pathway - (BioCarta via Pathway Interaction Database)
  3. Signalling to ERK5 - (Reactome via Pathway Interaction Database)
  4. Trk receptor signaling mediated by the MAPK pathway - (Pathway Interaction Database NCI-Nature Curated)

Curated Information ?

No related diseases are available

Publications related to MAP2K5: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nature genetics. 2007. Winkelmann Juliane, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. The Journal of biological chemistry. 1997. Kroll J, et al. PubMed


MP2K5_HUMAN (Q13163)
Comparative Toxicogenomics Database:
HumanCyc Gene:

Common Searches